Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 178

1.

Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer.

Liang G, Zhu Y, Ali DJ, Tian T, Xu H, Si K, Sun B, Chen B, Xiao Z.

J Nanobiotechnology. 2020 Jan 9;18(1):10. doi: 10.1186/s12951-019-0563-2.

2.

Clinical application of obinutuzumab for treating chronic lymphocytic leukemia.

Luan C, Chen B.

Drug Des Devel Ther. 2019 Aug 19;13:2899-2909. doi: 10.2147/DDDT.S212500. eCollection 2019. Review.

3.

Sorcin: a novel potential target in therapies of cancers.

Zhou X, Wu X, Chen B.

Cancer Manag Res. 2019 Aug 5;11:7327-7336. doi: 10.2147/CMAR.S208677. eCollection 2019.

4.

Screening of key genes associated with R‑CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B‑cell lymphoma.

Liu R, Chen Z, Wang S, Zhao G, Gu Y, Han Q, Chen B.

Mol Med Rep. 2019 Oct;20(4):3679-3690. doi: 10.3892/mmr.2019.10627. Epub 2019 Aug 29.

5.

Profiling of Exosomal Biomarkers for Accurate Cancer Identification: Combining DNA-PAINT with Machine- Learning-Based Classification.

Chen C, Zong S, Liu Y, Wang Z, Zhang Y, Chen B, Cui Y.

Small. 2019 Oct;15(43):e1901014. doi: 10.1002/smll.201901014. Epub 2019 Sep 3.

PMID:
31478613
6.

Inhibition of bleomycin-induced pulmonary fibrosis in mice by the novel peptide EZY-1 purified from Eucheuma.

Yu H, Zhang Z, Huang H, Wang Y, Lin B, Wu S, Ma J, Chen B, He Z, Wu J, Zhao Z, Zhang H.

Food Funct. 2019 Jun 19;10(6):3198-3208. doi: 10.1039/c9fo00308h.

PMID:
31165849
7.

Combination of drugs and carriers in drug delivery technology and its development.

Du Y, Chen B.

Drug Des Devel Ther. 2019 Apr 30;13:1401-1408. doi: 10.2147/DDDT.S198056. eCollection 2019. Review.

8.

Quizartinib (AC220): a promising option for acute myeloid leukemia.

Zhou F, Ge Z, Chen B.

Drug Des Devel Ther. 2019 Apr 8;13:1117-1125. doi: 10.2147/DDDT.S198950. eCollection 2019. Review.

9.

The inhibitory effect of tachyplesin I on thrombosis and its mechanisms.

Li H, Liu B, Wu J, Yu H, Huang H, Chen X, Chen B, Wu S, Ma J, Liu W, Chen X, Lan L, He Z, Zhang H.

Chem Biol Drug Des. 2019 Sep;94(3):1672-1679. doi: 10.1111/cbdd.13570. Epub 2019 Jun 12.

PMID:
31108023
10.

Applications of daunorubicin-loaded PLGA-PLL-PEG-Tf nanoparticles in hematologic malignancies: an in vitro and in vivo evaluation.

Bao W, Liu R, Xia G, Wang F, Chen B.

Drug Des Devel Ther. 2019 Apr 8;13:1107-1115. doi: 10.2147/DDDT.S195832. eCollection 2019.

11.

P-Glycoprotein Antibody Decorated Porous Hydrogel Particles for Capture and Release of Drug-Resistant Tumor Cells.

Ma X, Zhao Z, Wang H, Liu Y, Xu Y, Zhang J, Chen B, Li L, Zhao Y.

Adv Healthc Mater. 2019 Jul;8(13):e1900136. doi: 10.1002/adhm.201900136. Epub 2019 Apr 15.

PMID:
30985092
12.

Mechanisms of drug resistance in acute myeloid leukemia.

Zhang J, Gu Y, Chen B.

Onco Targets Ther. 2019 Mar 11;12:1937-1945. doi: 10.2147/OTT.S191621. eCollection 2019. Review.

13.

Toxic effects of magnetic nanoparticles on normal cells and organs.

Jiang Z, Shan K, Song J, Liu J, Rajendran S, Pugazhendhi A, Jacob JA, Chen B.

Life Sci. 2019 Mar 1;220:156-161. doi: 10.1016/j.lfs.2019.01.056. Epub 2019 Feb 1. Review.

PMID:
30716338
14.

SERS-based dynamic monitoring of minimal residual disease markers with high sensitivity for clinical applications.

Wang Y, Zong S, Li N, Wang Z, Chen B, Cui Y.

Nanoscale. 2019 Jan 31;11(5):2460-2467. doi: 10.1039/c8nr06929h.

PMID:
30671571
15.

Nano in nano: Biosynthesized gold and iron nanoclusters cargo neoplastic exosomes for cancer status biomarking.

Rehman FU, Du T, Shaikh S, Jiang X, Chen Y, Li X, Yi H, Hui J, Chen B, Selke M, Wang X.

Nanomedicine. 2018 Nov;14(8):2619-2631. doi: 10.1016/j.nano.2018.07.014. Epub 2018 Aug 18.

PMID:
30130583
16.

Evaluation of Multidrug Resistance of Leukemia Using Surface-Enhanced Raman Scattering Method for Clinical Applications.

Wang Y, Zong S, Wu L, Zhang Y, Wang Z, Wang Z, Chen B, Cui Y.

ACS Appl Mater Interfaces. 2018 Aug 1;10(30):24999-25005. doi: 10.1021/acsami.8b02917. Epub 2018 Jul 23.

PMID:
29996649
17.

Acute myeloid leukemia carrying ETV6 mutations: biologic and clinical features.

Zhou F, Chen B.

Hematology. 2018 Oct;23(9):608-612. doi: 10.1080/10245332.2018.1482051. Epub 2018 Jun 12. Review.

PMID:
29894279
18.

Folic Acid-Functionalized Hybrid Photonic Barcodes for Capture and Release of Circulating Tumor Cells.

Luan C, Wang H, Han Q, Ma X, Zhang D, Xu Y, Chen B, Li M, Zhao Y.

ACS Appl Mater Interfaces. 2018 Jun 27;10(25):21206-21212. doi: 10.1021/acsami.8b06882. Epub 2018 Jun 15.

PMID:
29882648
19.

Evaluation of latent membrane protein 1 and microRNA-155 for the prognostic prediction of diffuse large B cell lymphoma.

Wu X, Wang F, Li Y, Wang X, Liu P, Zhang H, Ge Z, Zhang X, Gao C, Chen B.

Oncol Lett. 2018 Jun;15(6):9725-9734. doi: 10.3892/ol.2018.8560. Epub 2018 Apr 24.

20.

CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia.

Luo H, Wang F, Zha J, Li H, Yan B, Du Q, Yang F, Sobh A, Vulpe C, Drusbosky L, Cogle C, Chepelev I, Xu B, Nimer SD, Licht J, Qiu Y, Chen B, Xu M, Huang S.

Blood. 2018 Aug 23;132(8):837-848. doi: 10.1182/blood-2017-11-814319. Epub 2018 May 14.

Supplemental Content

Loading ...
Support Center